Avatar
Benzinga @benzinga.com · Detroit 🇺🇸· 2 t

#Biopharmaceuticals #Neuroscience #HealthcareInnovation

Link Preview
www.benzinga.com
Xenon to Present at the 44th Annual J.P. Morgan Healthcare Conference - Xenon Pharmaceuticals (NASDAQ:XENE)
VANCOUVER, British Columbia and BOSTON, Jan.
Avatar
Benzinga @benzinga.com · Detroit 🇺🇸· 2 t

#GeneticMedicine #Biopharmaceuticals #Leadership

Link Preview
www.benzinga.com
ElevateBio Appoints Christopher Murphy as Chief Executive Officer and Member of the Board of Directors
WALTHAM, Mass.
Avatar
Benzinga @benzinga.com · Detroit 🇺🇸· 2 t

#Pelthos #Xeglyze #Biopharmaceuticals

Link Preview
www.benzinga.com
Pelthos Therapeutics Acquires Xeglyze® (abametapir) Topical Treatment for Head Lice - Pelthos Therapeutics (AMEX:PTHS)
Acquisition adds complementary asset to the Pelthos commercial portfolioXeglyze is a novel, FDA-approved prescription medication indicated for the topical treatment of head lice infestation in patients 6 months of age and older DURHAM, N.
Avatar
Benzinga @benzinga.com · Detroit 🇺🇸· 2 t

#Biopharmaceuticals #GeneticDiseases #HealthcareConference

Link Preview
www.benzinga.com
BridgeBio to Participate in the J.P. Morgan Healthcare Conference - BridgeBio Pharma (NASDAQ:BBIO)
PALO ALTO, Calif.
Avatar
Benzinga @benzinga.com · Detroit 🇺🇸· 2 t

#Biopharmaceuticals #LiverDisease #FDAApproval

Link Preview
www.benzinga.com
Altimmune Receives FDA Breakthrough Therapy Designation for Pemvidutide in MASH - Altimmune (NASDAQ:ALT)
GAITHERSBURG, Md.
Avatar
NASDAQ Stock Market @nasdaq.com · New York City 🇺🇸· 2 t

#biopharmaceuticals #cancerresearch #clinicaltrials

Link Preview
www.nasdaq.com
HUTCHMED Begins Phase 3 Part Of Phase 2/3 Surufatinib-Camrelizumab Combo Study In Pancreatic Cancer
(RTTNews) - HUTCHMED (China) Ltd (HCM, HCM.